Clinical Trial

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label Phase II clinical study, with the main objective being to evaluate the investigator-assessed objective response rate of JS212 in combination therapy for advanced lung cancer. The aim is to explore the safety, tolerability, and preliminary efficacy of JS212 combined with JS207, Toripalimab, JS213 combined or not combined with chemotherapy.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-19
Trial Details
NCT Number NCT07309276
Lead Sponsor Shanghai Junshi Bioscience Co., Ltd.
Conditions Advanced Lung Cancer
Enrollment 864 participants
Start Date 2026-01-23
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-11-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-18